Cost Effectiveness in Alveolar Bone Grafting in Patients with Cleft Lip and Palate
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Jan 15, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different methods for a surgical procedure called alveolar bone grafting, which is often needed for children with cleft lip and palate. The researchers want to see if using a special type of bone material called Bone Morphogenic Protein (BMP) combined with Demineralized Bone Matrix (DBM) is more cost-effective and can help patients experience less pain after surgery compared to using their own bone from the hip, known as Iliac Crest Bone Graft (ICBG). They will also check if both methods heal the bone similarly.
To participate in this trial, patients need to be between 2 and 18 years old and have a cleft lip and palate with a specific type of bone defect. They should also have been evaluated and approved by an orthodontist for the surgery. Participants can expect to be involved in a study that may help improve surgical options for future patients, and they will receive care from experienced medical professionals throughout the process. Importantly, the trial is currently recruiting participants, and it welcomes patients of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with CLP(unilateral or bilateral)
- • Radiographically evident open bone defect of the alveolus
- • Dentition evaluated by orthodontist and cleared for ABG surgery
- Exclusion Criteria:
- • Patients without CLP
- • Previous failed repair of alveolar cleft
- • Patients who have previously undergone successful ABG
- • Patients without an alveolar defect
- • Patients whose parents refuse to consent to randomization
- • Patients who have a syndromic CLP
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Matthew Greives, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials